Navigation Links
DelMar Pharmaceuticals Gives Quarterly Shareholder Update
Date:11/11/2013

I/II dose-escalation trial designed to assess the safety and preliminary efficacy of our lead product candidate, VAL-083, for the treatment of GBM.  

The results reported to date have shown promising drug activity and we believe that VAL-083 represents a potential new treatment option for brain tumor patients who have failed or are unlikely to benefit from today's standard of care.  More than half of patients fail the currently approved treatments.

The goal of our current clinical trial is to establish the optimal VAL-083 dosing regimen for both safety and efficacy in a U.S.-based GBM patient population. This dose would then be advanced into a Phase III GBM registration study, which we expect to commence in mid-2014 . During the past quarter, the U.S. Food and Drug Administration (FDA) undertook a detailed safety review of the Phase I/II trial and allowed us to accelerate our dose escalation program.  While this modification is unlikely to shorten the trial due to the length of our discussions with the FDA throughout this review, we should realize significant cost savings as fewer patients will be exposed to sub-optimal doses within the escalation study. We will present additional data from the ongoing Phase I/II trial during the Society for NeuroOncology (SNO) Annual Meeting on Friday November 22, 2013. 

We Are Strengthening Our Intellectual Property Portfolio
We have filed a broad portfolio of new patent applications to protect our intellectual property. Our patent applications claim compositions and methods related to the use of VAL-083 and related compounds as well as methods of synthesis and quality controls for the manufacturing process of VAL-083. In addition to our patent portfolio, VAL-083 has been granted Orphan Drug protection for the treatment of glioma, including GBM, in both the U.S. and Europe.  The orphan drug designation provides VAL-0
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Potential Treatment for Three Chemotherapy Resistant Cancers
2. DelMar Pharma reviews glioblastoma clinical trials and new therapeutic development on CEOLIVE.TV
3. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
4. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
5. DelMar Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. DelMar Pharmaceuticals Presents Additional Clinical Data from Ongoing Brain Cancer Study at ASCO
7. DelMar Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com June 6th
8. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
10. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
11. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014  Today the US Surgeon General issued ... sun tanning or sun burns stating they can lead directly ... Boris Lushniak , says that "skin cancer is a ... too much exposure to indoor and outdoor ultraviolet light is ... Aesthetic Medicine, in Boca Raton, Florida , ...
(Date:7/30/2014)... BURLINGTON, Mass. , July 30, 2014 /PRNewswire/ ... United States preclinical animal research imaging ... trend toward multimodality imaging, such as combining computed ... and optical imaging. This demand stems from the ... publication requirements among scientific journals, which will spur ...
(Date:7/30/2014)... Cynosure, Inc. (NASDAQ: CYNO ), a ... minimally invasive applications, today announced that the Board of Directors ... Financial Officer Timothy W. Baker to President of ... to serve as CFO and will take the title of ... Chief Executive Officer. "Tim has been a ...
Breaking Medicine Technology:Indoor and Outdoor Sun Tanning or Sun Burns Directly Linked to Deadly Melanoma Skin Cancer 2Growing Popularity of Multimodality Imaging Will Drive the Preclinical Animal Research Imaging System Market 2Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2
... FDA, Favorable Scientific Advice from EMEA and Phase 3 Plans ... Cell Lung ... Dr. Giuseppe Giaccone,Chief of the Medical Oncology Branch at the ... Phase 2 trial with talactoferrin alfa in non-small cell,lung cancer ...
... End-User Satisfaction, ... of Care Improvements, ORLANDO, Fla., Feb. 25 ... Society (HIMSS) 2008 Annual,Conference and Exhibition in Orlando, ... faith-based healthcare system in Nebraska and southwestern,Iowa, announced ...
Cached Medicine Technology:Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 2Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 3Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 4Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 5Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 6Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting 7Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing 2Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing 3Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing 4Alegent Health Sees Positive Results From Recent Clinician Usability Study Collaboration With Siemens and Motion Computing 5
(Date:7/30/2014)... (PRWEB) July 30, 2014 Nationally recognized ... CNE, ANEF, who since September 2013 has served as ... became the new dean of the College of Nursing ... move marries her leadership of the NLN, as the ... the top-ranked academic nursing and research institutions in the ...
(Date:7/30/2014)... Within weeks freshman will begin to pour onto college ... will be a time of growth and the start to something ... may not be as easy as it looks. Some sources ... major at least once and many will switch two or three ... are exacerbated when switching in the later years of college. According ...
(Date:7/30/2014)... Throughout the month of August, Restore ... cancer screenings. Using a new technological tool called The ... disease in its early stages. , Oral cancer can ... throat and other areas in and around the mouth. ... Ends Results (SEER) program, 30 percent of oral cancers ...
(Date:7/30/2014)... Cucamonga, CA (PRWEB) July 30, 2014 Serial ... learning how to make millions. However, like most people, in ... Determined to find a better way, Paul carefully studied ... wealth and those who do not. Based on the knowledge ... to not only improve his life and health, but also ...
(Date:7/30/2014)... HealthDay Reporter WEDNESDAY, July 30, 2014 ... to develop dementia, but researchers have been unable to explain ... Specifically, they haven,t been able to figure out the direction ... on dementia, or does dementia cause people to become depressed? ... journal Neurology sheds more light on the mystery. ...
Breaking Medicine News(10 mins):Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 2Health News:National League for Nursing Congratulates League President Marsha Adams on Appointment as Dean of College of Nursing at University of Alabama-Huntsville 3Health News:Advice to College Freshman from Author Garrett Miller 2Health News:Advice to College Freshman from Author Garrett Miller 3Health News:Restore Dental Offers Complimentary Oral Cancer Screenings in August 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 2Health News:Paul Mata Kicks off 3-day Wealth Bootcamp on September 11th 3Health News:Scientists Shed Light on Link Between Depression, Dementia 2Health News:Scientists Shed Light on Link Between Depression, Dementia 3
... for UGIB should be performed within 24 hour from the admission. ... it should be performed either very early i.e. within 2 ... 6, 12 or 24 hour. Therefore, optimal timing for urgent endoscopy ... article to be published on August 28, 2008 in the ...
... 9 Heritage Victor Valley,Medical Group announced today ... Club. The Victorville Senior Citizen Club sponsors,educational, social ... The computers will be used for work stations ... programs at the Club., "The Victorville Senior ...
... Brinks Hofer Gilson & Lione, one of,the largest intellectual ... that Jacob Cheung-Ka Ong has joined the firm,s Salt ... Cheung-Ka Ong received a B.S. in neuroscience from Brigham ... University of,California-San Diego, La Jolla. He received his J.D. ...
... Bias Correction of Familial Risk Estimates Increases Estimated Melanoma ... , The relative risk of familial melanoma increases substantially ... a large cohort study. The relative risk of familial ... substantially with the correction. , Researchers have used the ...
... (Sept. 9, 2008) Both higher fish consumption and ... development in infants, according to a study of mothers ... breastfeeding were independently beneficial. , "These results, together with ... and the United Kingdom, provide additional evidence that moderate ...
... Firm Will Grow Through Leadership Development and Technological Efficiency ... ... Ga. (Vocus) September 9, 2008 -- http://www.jacksonhealthcare.com/companies.aspx ... of Alpharetta, Ga.-based http://www.locumtenens.com/new_leader08 [LocumTenens.com]. Working ...
Cached Medicine News:Health News:Also in the Sept. 9 JNCI 2Health News:Also in the Sept. 9 JNCI 3Health News:Eating fish while pregnant, longer breastfeeding, lead to better infant development 2Health News:Eating fish while pregnant, longer breastfeeding, lead to better infant development 3Health News:R. Shane Jackson Named President of LocumTenens.com 2Health News:R. Shane Jackson Named President of LocumTenens.com 3
... Finnpipette BioControl multichannel has ... as the single channel ... fits allseven multichannel and ... cone modules. Both pipettes ...
... and best value in high performance electronic ... ultra lightweight design reduce hand fatigue and ... lever tip ejector , Color coding for ... or for greater performance use Hamilton AdvanTip ...
... pro Electronic Pipette is ideal for all ... easy-to-follow display, ergonomically-placed operating buttons, and various ... pipetting and diluting make this a lab ... of a manual pipette without any adverse ...
... The Research pro Electronic Pipette is ... the laboratory. Its easy-to-follow display, ergonomically-placed operating ... pipetting, dispensing, reverse pipetting and diluting make ... the simple functions of a manual pipette ...
Medicine Products: